A Phase 1/2 interventional study of VX-670 and Placebo in Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 26 sites in 10 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 1/2, reaches primary completion later than 5 of the 26 other live ones, and was the 29th registered.
126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 3 started in 2024.
This study's enrollment of 47 is above the median of 40 across 67 interventional studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
Vertex Pharmaceuticals Incorporated has 2 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Key Inclusion Criteria:
- Documented clinical diagnosis of DM1 with age of onset greater than (>) 1 year of age and documented positive genetic test for DM1 in the subject with cytosine thymine guanine (CTG) repeat of at least 100
Key Exclusion Criteria:
- History of any illness or any clinical condition as pre-specified in the protocol
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants will be randomized to receive a single dose of different dose levels of VX-670.
Drug: VX-670
Participants will be randomized to receive single dose of placebo matched to VX-670.
Drug: Placebo
Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A.
Drug: VX-670
Participants will be randomized to receive single or multiple doses of placebo matched to VX-670.
Drug: Placebo
Solution for intravenous administration.
Solution for intravenous administration.
Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Time frame: Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168
Part A: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma
Time frame: From Day 1 up to Day 42
Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma
Time frame: From Day 1 up to Day 42
Part B: Maximum Observed Concentration (Cmax) of VX-670 and its Active Component in Plasma After Each Dose
Time frame: From Day 1 up to Day 168
Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-670 and its Active Component in Plasma After Each Dose
Time frame: From Day 1 up to Day 168
Part B: Concentration of VX-670 and its Active Component in Muscle
Time frame: Baseline, Day 15 and Day 120
Part B: Change in Splicing Index in Muscle Biopsy
Time frame: Baseline, Day 15 and Day 120
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →